Pro-inflammatory and anti-inflammatory compounds exert similar effects on Pglycoprotein in blood-brain barrier endothelial cells

DOI: 10.1111/jphp.12893

Citation for published version (APA):

Published in:
Journal of Pharmacy and Pharmacology

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.
Pro-inflammatory and anti-inflammatory compounds exert similar effects on P-glycoprotein in blood-brain barrier endothelial cells

Torres-Vergara P.1,2, Penny J1

1. Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Medicine, Biology and Health, University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom

2. Department of Pharmacy, Faculty of Pharmacy, University of Concepción, Barrio Universitario, Concepción, Chile

Corresponding author e-mail: jeffrey.penny@manchester.ac.uk

Abstract

Objectives: The effects of anti-inflammatory glucocorticoids dexamethasone (DX) and hydrocortisone (HC), pro-inflammatory cytokine interleukin-1β (IL-1β) and dietary long-chain polyunsaturated fatty acids (PUFAs) on expression and activity of the ATP-binding cassette transporter P-glycoprotein (P-GP) were studied in porcine brain endothelial cells (PBECs).

Methods: Primary PBECs were treated for 24 h with glucocorticoids, IL-1β and long-chain PUFAs. P-GP activity was determined by measuring intracellular calcein accumulation and P-GP expression by Western blotting. The effect of PUFAs on membrane fluidity was assessed by fluorescence recovery after photobleaching (FRAP).

Key findings: Dexamethasone, HC, and IL-1β significantly increased P-GP expression and activity. The effect of IL-1β was attenuated by the IL-1 receptor antagonist (IL-1RA). This is the first report of the combined actions of IL-1β and IL-1RA on P-GP expression and the first evidence of glucocorticoid-mediated P-GP up-regulation in PBECs. Arachidonic acid (AA), docosahexaenoic acid (DHA) and eicosapentenoic acid (EPA) significantly decreased P-GP activity without affecting expression or membrane fluidity. AA, DHA and EPA counteracted IL-1β-mediated increases in P-GP activity, whilst AA and EPA, but not DHA, counteracted glucocorticoid-mediated increase in P-GP activity.

Conclusions: Whilst glucocorticoids and IL-1β possess opposing actions in inflammation, they demonstrate functional consistency by increasing P-GP expression and activity in PBECs.
Keywords: P-glycoprotein, cytokine, interleukin, glucocorticoids, polyunsaturated fatty acid, PUFA, blood-brain barrier, endothelial cell.

Introduction

P-glycoprotein (P-GP), an ATP-binding cassette (ABC) transporter, expressed in blood-brain barrier (BBB) endothelial cells plays a key role in influencing central nervous system (CNS) drug disposition (1). P-glycoprotein activity has been widely reported to be modulated by direct interaction of inhibitors with the drug-binding sites of the transporter (2, 3).

However, modulation of P-GP activity via changes in gene expression has received increased attention. Studies report activation of both membrane and nuclear receptors in brain endothelial cells, leading to activation of signalling pathways, elicit changes in the expression of P-GP, and other ABC transporters, at both the gene and protein levels (4, 5).

Pro-inflammatory cytokines, including IL-1β, IL-6 and TNFα, are key elements in development and progression of multiple disease conditions and the effects of acute and chronic inflammatory conditions, mediated by pro-inflammatory cytokines, on the expression and activity of P-GP have been studied both in in vitro and in vivo models (1, 6). Since many therapeutic drugs are P-GP substrates, it is feasible that the pathophysiological mechanisms associated with disease conditions could influence CNS drug disposition.

Whilst studies consistently report that inflammatory conditions cause changes in the expression of P-GP at the protein level, these changes are both model- and time-dependent (7, 8). For example, Hartz et al. (7) demonstrated that a 6-hour treatment with TNFα up-regulated P-GP activity and expression in isolated rat capillaries, but Iqbal et al. (8) reported that a 24 h treatment with the same cytokine down-regulated P-GP activity in primary brain endothelial cell cultures isolated from gestating and post-natal guinea pigs.
The majority of studies investigating the effects of sterile and non-sterile inflammatory conditions on P-GP expression and function at the blood-brain barrier have been undertaken in rodent-based *in vivo* and *in vitro* models (7-9), with the amount of work performed in models derived from higher species, particularly porcine (10) and human (11-13) cell-based models, being comparatively less.

The extent of an inflammatory response is a balance between pro- and anti-inflammatory factors. Glucocorticoids possess anti-inflammatory activity, but are also reported to affect expression of ABC transporters in mammalian brain endothelial cells (14). However, the findings of the effects of glucocorticoids on P-GP expression in porcine-based BEC models are conflicting, as von Wedel-Parlow et al. (10) demonstrated HC decreased P-GP expression whilst Alms et al. (15) reported DX had no effect on P-GP activity.

Regulation of P-GP expression and activity is complex and multifactorial. The dietary-derived long chain polyunsaturated fatty acids DHA and EPA, which have been reported to exert anti-inflammatory actions (16), have also been demonstrated to decrease P-GP activity in CaCo-2 cells (17). However, AA, a prostaglandin precursor that is considered pro-inflammatory (18), has exhibited mixed effects on P-GP activity, with studies reporting P-GP induction (19) and P-GP inhibition (17).

Long-chain PUFAs may act through multiple mechanisms, but one that has received much attention is their ability to provoke changes in membrane fluidity (20). Such changes are thought to modulate the activity of membrane-bound receptors (16) and ABC transporters embedded within lipid rafts (21) and a number of reports have described the chemosensitising effects of PUFAs on cancer cell lines resistant to therapeutics that are P-GP substrates (22, 23). However, to date, no studies have investigated the ability of long-chain PUFAs to modulate the activity of P-GP in blood-brain barrier endothelial cells that express high levels of the transporter. Furthermore, previous studies have primarily looked at the effects of single inflammatory mediators on P-GP expression. The current studies are the first to investigate the interplay between pro-inflammatory mediators (IL-1β and AA) and anti-inflammatory
mediators (DX, HC, DHA and EPA) and their combined effects on both P-GP expression and functional activity in primary PBECs.

Our previous studies have demonstrated this model is competent in terms of demonstrating key physiological features of the blood-brain barrier, including formation of a highly restrictive endothelial cell monolayer with high transendothelial electrical resistance, expression of functional ABC efflux transporters (24) and interleukin-1 receptor (25).

Materials and methods

Reagents and materials

All chemicals and mouse anti-β-actin-N-terminal monoclonal antibody were obtained from Sigma-Aldrich, UK. Porcine recombinant IL-1β and IL-1RA were obtained from R&D Systems, USA. Calcein-AM, cell culture reagents and Vybrant® DiI dye were purchased from Life Technologies, UK. Bovine plasma-derived serum was obtained from First Link Biochemicals, UK. Collagenase, DNAase and trypsin were obtained from Worthington Biochemicals, USA. Mouse C219 monoclonal antibody was obtained from Calbiochem, USA and horseradish peroxidase (HRP)-conjugated sheep anti-mouse antibody obtained from General Electric Life Sciences, UK. Clarity ECL developing reagent was from Bio-Rad, UK. The CTX-TNA2 rat astrocyte cell line was obtained from the American Type Culture Collection (ATCC) repository.

Culturing of the CTX-TNA2 rat astrocyte cell line and harvesting of astrocyte-conditioned medium

The CTX-TNA2 cell line was cultured in phenol red-free high-glucose DMEM, supplemented with 10 % (v/v) FBS and 1 % (v/v) penicillin/streptomycin. Astrocyte-conditioned medium (ACM) was harvested when astrocytes reached 40 - 60 % confluence, filtered through a 0.22 μm sterile syringe filter and stored at -20 °C.
Isolation and culturing of porcine brain microvessels

Microvessels were isolated from fresh porcine brains based on the protocol of Skinner et al (2009). Cryopreserved microvessels were thawed and resuspended in phenol red-free low-glucose DMEM supplemented with 10 % (v/v) bovine plasma derived serum, 2 mM L-glutamine, 1 % (v/v) penicillin/streptomycin and 125 µg.ml\(^{-1}\) heparin (PBEC growth medium), seeded into rat type I collagen (125 µg.ml\(^{-1}\))/fibronectin (7.5 µg.ml\(^{-1}\)) coated 6-well plates and incubated at 37 °C with 5 % CO\(_2\) for 24 h. Microvessels were treated with puromycin, 4 µg.ml\(^{-1}\) for 48 h and subsequently maintained in 1:1 PBEC growth medium:ACM for 7 days (Western blotting) or subcultured on day 5 into collagen/fibronectin-coated 96-well plates, 20,000 cells/well (calcein-AM assay) and 30,000 cells/well in Ibidi µ–Slide 8-well microscopy chambers (FRAP experiments).

Treatment with pro-inflammatory and anti-inflammatory compounds

PBECs were maintained in treatment medium comprised of phenol red-free low-glucose DMEM supplemented with 1 % (v/v) FBS and 2 mM L-glutamine. After 1 h equilibration, PBECs were incubated with the glucocorticoids DX and HC, the cytokines IL-1β, IL-1RA and the long chain PUFAs AA, DHA and EPA (at concentrations stated in individual Figures) at 37 °C with 5 % CO\(_2\) for 24 h. Glucocorticoids stock solutions were made up in DMSO, sodium salts of PUFAs were dissolved in absolute ethanol and cytokines were reconstituted in sterile phosphate buffered saline (PBS). For all treatments, the concentration of DMSO and ethanol never exceeded 0.1 % (v/v) and 0.05 % (v/v), respectively, and this concentration of solvent did not significantly affect ABCB1 activity. Compounds were used at non-cytotoxic concentrations, as determined in advance by the MTT assay.

Calcein-AM assay for measurement of P-glycoprotein activity

PBECs in 96-well plates were washed twice with warm PBS and equilibrated with phenol red-free low-glucose DMEM supplemented with 2 mM L-glutamine at 37 °C with 5 %
CO₂ for 30 min. Where appropriate, cells were pre-incubated with the P-GP inhibitor verapamil (final concentration 10 µM) for 30 min.

PBEC monolayers were incubated with calcein-AM (final concentration 0.5 µM) for 30 min. washed twice with ice-cold PBS and 100 µl of PBS was added to each well. Fluorescence was measured immediately (excitation: 484 nm, emission 530 nm) using a Safire multi-plate reader (Tecan, Switzerland) and expressed as relative fluorescence units (RFU) normalised to µg of protein. Protein content of cell lysates was determined using the Bradford reagent (Bio Rad, UK).

**Western blotting**

PBECs were treated with the selected compounds and lysed with 200 µl of Cellytic M solution. Lysates were centrifuged at 15000 x g at 4 ºC for 15 min and supernatants stored at -80 ºC. Protein content of cell lysates was determined using the Bradford reagent (Bio Rad, UK).

Fifteen µg protein was loaded on a 6 % SDS-polyacrylamide gel, electrophoresis carried out at 150 V and proteins were subsequently electrotransferred to polyvinylidene difluoride membranes. Membranes were incubated overnight with C219 monoclonal antibody for detection of P-GP (1:50) and mouse anti-β-actin-N-terminal monoclonal antibody (1:25,000) for 1.5 h. Membranes were washed with TBS-T then incubated with HRP-conjugated sheep anti-mouse antibody (1:2,500). Proteins were detected by enhanced chemiluminescence using the ChemiDoc imaging system (Bio Rad, UK) and images analysed with ImageJ software (National Institute of Health, USA).

**Fluorescence recovery after photobleaching**

PBECs in Ibidi µ–Slide 8-well microscopy chambers were treated with PUFAs, washed three times with warm Hank’s balanced salt solution and incubated for 20 min with Vybrant DiI reagent. After three 5 min washes, 300 µl of warm HBSS were added to each well.
Fluorescence recovery after photobleaching (FRAP) was analysed with a Leica TCS SP5 AOBS inverted confocal microscope (Leica, Germany) with an excitation wavelength of 568 nm. Bleaching was carried out in the region of interest (ROI) at 488 nm for 1 s.

Images were analysed with LAS AF lite software (Leica, Germany) and the extracted data processed using the double normalisation method (Kenworthy, 2007).

The post-bleaching portion of fractional fluorescence recovery curves over time were fitted under an exponential decay function, using the Prism 6.0 statistical software (GraphPad, USA), to obtain the half-time of recovery ($t_{1/2}$) parameter. The diffusion coefficient ($D$) was determined with the following equation (Yamamoto and Ando, 2013).

$$D = \frac{\omega^2}{4t_{1/2}}$$

Where $\omega$ is the radius of the focused laser beam.

**Statistical analysis**

Data are expressed as mean ± standard deviation and analysed with either the Mann-Whitney test or Kruskal-Wallis test with Dunn’s post hoc analysis, using Prism 6.0 statistical software (GraphPad, USA).

**Results**

**Effect of glucocorticoids on P-glycoprotein activity and expression**

PBECs were successfully isolated and maintained in culture (>99% purity) prior to treatment. Treatment of PBECs for 24 h with dexamethasone and hydrocortisone (at a concentration of 10 µM), significantly decreased ($P < 0.0001$) the intracellular accumulation of calcein by 25 % and 20 % respectively, suggesting increased P-GP activity (Figure 1A). Neither of the compounds affected cell viability at the concentration used.

Western blotting of whole cell lysates followed by densitometric analysis revealed expression of the P-GP transporter was significantly up-regulated ($P < 0.05$) after treatment with
the selected glucocorticoids (Figure 1B and 1C), confirming the effects of glucocorticoids on P-GP at a functional level.

**Figure 1.** Effects of glucocorticoids on P-GP activity and expression in brain endothelial cells. (A) effects of DX and HC on intracellular calcein accumulation, (B) effects of DX and HC on P-GP expression and (C) fold change in P-GP band intensity normalised to the β-actin loading control. Results are expressed as mean ± standard deviation of three independent experiments. *: P < 0.05, ****: P < 0.0001.

**Effect of the pro-inflammatory cytokine Interleukin-1β on P-glycoprotein activity and expression**

Treatment of PBECs with IL-1β decreased the intracellular accumulation of calcein, with this reduction being significant at concentrations of 1 ng.ml\(^{-1}\) (25 % reduction compared to the control, P < 0.0001) and above (Figure 2A). The specificity of the effect of IL-1β on P-GP activity was assessed using IL-1 receptor antagonist (IL-1RA). IL-1RA counteracted the IL-1β-mediated reduction in intracellular calcein accumulation, with levels of calcein accumulation reverting to a similar level observed in the control condition, (Figure 2B). Treatment of PBECs with 1,000 ng.ml\(^{-1}\) IL-1RA alone did not significantly affect intracellular calcein accumulation.

The IL-1β-mediated increase in P-GP activity and the counteracting effect of IL-1RA, were confirmed by Western blotting. Densitometric analysis demonstrated that IL-1β significantly (P < 0.05) up-regulated P-GP expression, whilst IL-1RA partially, but significantly (P < 0.05), attenuated this effect (Figures 2C and 2D).

**Figure 2.** Effects of IL-1β and IL-1RA on P-GP activity and expression in brain endothelial cells. (A) effect of IL-1β on P-GP activity, (B) effect of IL-1RA on IL-1β-induced P-GP activity, (C) effects of IL-1RA and IL-1β on P-GP expression and (D) the fold change in the P-GP band intensity normalised to the β-actin loading control. Results are expressed as mean ± standard deviation of three independent experiments (duplicate for IL-1RA single treatment). *: P < 0.05, **: P < 0.01, ***: P < 0.001, ****: P < 0.0001.
Effect of n-3 and n-6 PUFAs on P-glycoprotein activity and expression

Treatment of PBECs with AA, DHA and EPA for 24 h significantly increased the intracellular accumulation of calcein, reflecting reduced P-GP activity (Figure 3A).

Despite significantly reducing P-GP activity, AA, DHA or EPA did not significantly modify P-GP expression (Figures 3B and 3C).

Figure 3. Effects of long-chain PUFAs on P-GP activity and expression. (A) effects of AA, DHA and EPA on intracellular calcein accumulation and (B) effects of AA, DHA and EPA on P-GP expression. (C) fold change in the P-GP band intensity normalised to the β-actin loading control. Results are expressed as mean ± standard deviation of three independent experiments. ****: P < 0.0001.

Effect of PUFAs on glucocorticoid-induced and IL-1β–induced P-glycoprotein activity

Treatment of PBECs with IL-1β, DX and HC significantly increased P-GP functional activity, whilst treatment with AA, DHA and EPA significantly reduced P-GP activity. Therefore, the ability of PUFAs to reverse IL-1β-, DX- and HC-induced P-GP functional activity was investigated. AA, DHA and EPA counteracted IL-1β-mediated increases in P-GP activity in brain endothelial cells, reducing calcein accumulation to control values, whilst AA and EPA, but not DHA, counteracted the HC- and DX-mediated increases in P-GP activity (Table 1).

Table 1. Effect of AA, DHA and EPA on glucocorticoid- and IL-1β-induced P-GP activity, expressed as % RFU/µg protein. Single treatments with glucocorticoids, IL-1β and PUFAs were compared to their respective control. The effect of co-treatments on intracellular calcein accumulation was assessed by comparing the results of the co-treatments with the single treatments of glucocorticoid or IL-1β. Results are expressed as mean ± standard deviation of three independent experiments. #: glucocorticoid or IL-1β single treatments v/s control; §: PUFAs single treatments v/s control; §: co-treatments v/s glucocorticoid or IL-1β single treatments. #: §, *: P < 0.05; ##, §§, **: P < 0.01; ###, §§§, ***: P < 0.001; ####, §§§§, ****: P < 0.0001; ns: not significant.

In order to establish if the actions of AA, DHA and EPA occurred solely at the functional level, or whether the PUFAs modified P-GP expression, Western blotting of whole
cell lysates was performed. Western blotting and densitometric analysis confirmed that PUFAs did not affect IL-1β-, DX- and HC-induced P-GP expression (Figure 4).

**Figure 4.** Representative Western blots (A, C and E) and densitometric analysis (B, D, and F) of the effects of AA, DHA and EPA on (A) DX-induced P-GP expression, (B) HC-induced P-GP expression and (C) IL-1β-induced P-GP expression in brain endothelial cells.

**Effect of n-3 and n-6 PUFAs on membrane fluidity**

The PUFAs AA, DHA and EPA significantly reduced P-GP activity in porcine brain endothelial cells, independent of modifying P-GP expression. Since P-GP is an integral membrane protein, the effect of PUFAs on membrane fluidity was therefore analysed.

When PBECs were treated with AA, DHA and EPA, fitted average fractional fluorescence recovery curves were similar to controls. Treatment with AA, DHA and EPA did not significantly modify either the mobile fraction or the diffusion coefficient values of Dil18 when compared to control conditions, indicating a lack of effect of long-chain PUFAs on membrane fluidity at the concentrations employed in these studies (Figure 5).

**Figure 5.** The effect of AA, DHA and EPA on membrane fluidity of PBECs. (A) Average fitted fractional fluorescence recovery curves and (B) diffusion coefficients calculated from the half-lives obtained after exponential decay fitting of FRAP curves. Data are expressed as the mean ± standard deviation of three independent experiments.

**Discussion**

P-glycoprotein activity influences whole body pharmacokinetics and drug delivery to the CNS. Consequently, alteration of P-GP activity may impact CNS drug disposition and delivery efficacy.

Inflammatory conditions are associated with numerous pathological states that involve high levels of IL-1β (26, 27), including stroke (28) and psychiatric and neurodegenerative
conditions (27). Whilst the individual effects of IL-1β, or of anti-inflammatory glucocorticoids and PUFAs, on P-GP expression and activity have been reported previously (7, 11, 29), few studies have analysed the interplay between pro- and anti-inflammatory mediators on BBB P-GP the expression and activity (10). Therefore, the current study investigated the effects of pro- and anti-inflammatory compounds on P-GP expression and activity in primary PBECs.

In the current study, IL-1β increased P-GP activity and expression, which were attenuated by IL-1RA, confirming involvement of the IL-1β receptor. This is the first experimental evidence that IL-1RA antagonises IL-1β-mediated induction of an ABC transporter. The effects of IL-1β on P-GP expression are consistent with the studies of Zuloaga et al. (12) that demonstrated IL-1β increased P-GP expression in human BECs.

In contrast to the findings of the present work, von Wedel-Parlow et al. (10) and Iqbal et al. (8) reported IL-1β decreased P-GP activity in porcine and rodent BECs, respectively. Although neither characterised the downstream events, they suggested involvement of the canonical NF-κB signalling pathway. This issue represented an opportunity to test several NF-κB inhibitors including BAY-117082, luteolin, cardamonin and sulfasalazine. However, as none of them attenuated the actions of IL-1β (data not shown), these findings suggest the IL-1β-mediated induction of P-GP expression is more complex than thought and could involve the participation of other signalling pathways. Key candidates are the mitogen-activated protein kinase (MAPK) and c-Jun-N-terminal kinase (JNK) pathways which have been reported to be activated by pro-inflammatory cytokines IL-1β and tumour necrosis factor-α (30, 31).

The glucocorticoids hydrocortisone and dexamethasone up-regulated P-GP expression and activity. This is the first evidence of glucocorticoid-mediated P-GP up-regulation in PBECs, and is in agreement with Narang et al. (14) and Iqbal et al. (32, 33), who demonstrated dexamethasone increased P-gp expression and activity in rat and guinea pig BECs.

However, a lack of effect of HC and DX on P-GP in PBECs has been reported (10, 15). Alms et al. (15) suggested puromycin might hinder the inductive actions of glucocorticoids,
since puromycin is also a P-GP inducer. In the present studies both HC and DX significantly up-regulated P-GP expression and activity and this may be explained by differences in exposure times to puromycin; 48 h in the current studies compared to 72 h employed by Alms et al (15). This reduced exposure time is likely to result in less of an inductive effect by puromycin and a greater inductive effect of HC and DX (and IL-1β) on P-GP expression and activity.

Treatment with DHA, EPA and AA significantly increased intracellular calcein accumulation, potentially reflecting decreased P-GP activity. These findings are consistent with reports that long-chain PUFAs sensitise drug-resistant cells to chemotherapeutics that are P-GP substrates (17, 22, 23).

P-GP is localised in plasma membrane lipid rafts (21) and studies in drug resistant HT-29 cells (34) demonstrated DHA and EPA (but not AA) displaced cholesterol from lipid rafts, decreasing P-GP activity. Also, incorporation of PUFAs within the plasma membrane, decreases molecular order, affecting membrane fluidity (16, 35, 36). In the current study, the AA-, DHA- and EPA-mediated reduction in P-GP activity was associated with no change in P-GP expression level. To establish if the effects of long-chain PUFAs were through changes in plasma membrane fluidity, FRAP analysis was performed (37). Neither AA, EPA nor DHA significantly modified membrane diffusion coefficients.

One potential explanation for a change in P-GP activity with no change is membrane fluidity is that n-3 PUFAs, including DHA, increase the molecular order of lipid rafts, thereby affecting the activity of proteins embedded within these lipid microdomains (36). However, this does not explain why AA, an n-6 PUFA, elicited a similar effect as n-3 PUFAs on P-GP activity. Another possible explanation for reduced P-GP activity following exposure to DHA and EPA is PUFA-mediated internalisation of P-GP, as demonstrated by Gelsomino et al. (34). Therefore, further studies are required to determine if the changes in P-GP activity following treatment with long-chain PUFAs are due to alterations in membrane order, composition of lipid rafts and/or internalisation of the protein within the cell.
Co-treatment of PBECs with the P-GP inducer IL-1β and with PUFAs (AA, DHA and EPA) revealed PUFAs counteract IL-1β-mediated induction of P-GP activity. Similarly, AA and EPA, although not DHA, also counteract glucocorticoid (HC, DX)-mediated induction of P-GP activity.

Although glucocorticoids are anti-inflammatory and IL-1β is pro-inflammatory, they individually up-regulated P-GP expression and activity. In preliminary studies glucocorticoid and IL-1β co-treatments produced a synergistic effect on P-GP activity. HC increased P-GP activity by 20 % and treatment with IL-1β increased P-GP activity by 25 %. However, co-treatment with HC and IL-1β increased P-GP activity by 40 % (data not shown).

Synergism between anti- and pro-inflammatory mediators has been reported previously. Iqbal et al (33) demonstrated DX enhanced the effect of IL-1β on P-gp activity, proposing the synergistic effect is a result of the DX-mediated increase in IL-1 receptor type I expression, whose activation by IL-1β enhanced P-gp activity.

Whilst glucocorticoids routinely act through the glucocorticoid receptor pathway, the downstream events involved in the IL-1β-mediated regulation of P-GP expression remain unclear as mentioned above, and further studies are underway to establish the mechanism by which IL-1β regulates P-GP expression in blood-brain barrier endothelial cells.

**Conclusions**

In this study, the pro-inflammatory cytokine IL-1β and the anti-inflammatory glucocorticoids DX and HC induced activity of the ABC transporter P-GP in porcine brain endothelial cells, whilst the long chain omega-3 PUFAs DHA and EPA and the omega-6 PUFA AA attenuated this induction, independent of altering membrane fluidity. This outcome demonstrates that anti-inflammatory molecules do not necessarily counteract the actions of pro-inflammatory molecules in all biochemical and physiological processes.

Acute and chronic inflammation, and IL-1β production, is associated with many widespread medical conditions, and has the potential to regulate P-GP efflux activity within the
blood-brain barrier. Consequently, brain penetration of endogenous mediators and xenobiotics including therapeutic drugs may be altered in inflammatory conditions, and dietary-derived PUFAs could help restore P-GP activity to levels observed in non-inflammatory conditions.

**Declarations**

**Conflict of interests**

The authors declare they have no conflict of interest.

**Acknowledgements**

The National Commission of Science and Technological Research (CONICYT), Chile, funds Mr. Torres-Vergara’s scholarship (reference: 14.598.737-7). Mr. Torres-Vergara also acknowledges the support from the University of Concepción, Chile and the Division of Pharmacy & Optometry, University of Manchester, England, UK. The authors would like to thank the technical support provided by Dr. Steven Marsden from the Bioimaging Unit, Faculty of Biology, Medicine and Health, University of Manchester. Part of this work was presented at the 2015 Annual Conference of the British Pharmacological Society in London, United Kingdom.

**References**


12. Zuloaga KL, Swift SN, Gonzales RJ, Wu TJ, Handa RJ. The androgen metabolite, 5alpha-androstane-3beta,17beta-diol, decreases cytokine-induced cyclooxygenase-2,


Table 1.

<table>
<thead>
<tr>
<th></th>
<th>No PUFA</th>
<th>AA 3 µM</th>
<th>DHA 5 µM</th>
<th>EPA 3 µM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>137.1 ± 11.2</td>
<td>119.7 ± 8.6</td>
<td>126.7 ± 11.4</td>
</tr>
<tr>
<td>No DX</td>
<td>100.0 ± 13.3</td>
<td>§§§§</td>
<td>§</td>
<td>§§§</td>
</tr>
<tr>
<td>DX 10 µM</td>
<td>78.7 ± 7.8</td>
<td>114.8 ± 18.4</td>
<td>89.9 ± 16.7</td>
<td>94.6 ± 11.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>****</td>
<td>ns</td>
<td>*</td>
</tr>
<tr>
<td>No HC</td>
<td>100.0 ± 8.9</td>
<td>164.6 ± 34.8</td>
<td>162.1 ± 29.5</td>
<td>158.2 ± 22.8</td>
</tr>
<tr>
<td>HC 10 µM</td>
<td>79.7 ± 12.4</td>
<td>126.6 ± 23.0</td>
<td>100.3 ± 23.3</td>
<td>108.4 ± 22.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>****</td>
<td>ns</td>
<td>**</td>
</tr>
<tr>
<td>No IL-1β</td>
<td>100.0 ± 9.3</td>
<td>166.3 ± 43.8</td>
<td>173.9 ± 42.1</td>
<td>130.8 ± 15.1</td>
</tr>
<tr>
<td>IL-1β 1 ng.ml⁻¹</td>
<td>74.7 ± 7.9</td>
<td>107.3 ± 24.6</td>
<td>90.95 ± 11.1</td>
<td>100.0 ± 21.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>****</td>
<td>*</td>
<td>**</td>
</tr>
</tbody>
</table>
Figure 1
Figure 3

A

![Graph showing % RLU/μg protein for Control, AA 3 μM, DHA 5 μM, and EPA 3 μM. The graph includes error bars and statistical significance (****).](image)

B

![Western blot analysis for P-GP and β-actin with corresponding molecular weight markers (kDa).](image)

C

![Bar graph showing fold change for AA 3 μM, DHA 5 μM, and EPA 3 μM.](image)
Figure 4

A

B

C

D

E

F
Figure 5

A

Fractional fluorescence recovery

Time [s]

DMEM
EtOH 0.05 % (v/v)
AA 3 μM
DHA 5 μM
EPA 3 μM

B

μm^2.s^{-1}

DMEM
EtOH 0.05 % (v/v)
AA 3 μM
DHA 5 μM
EPA 3 μM

ns